A phase 3, global, multicenter, open-label study to investigate the efficacy of elbasvir/grazoprevir fixed-dose combination for 8 weeks in treatment-naïve, HCV GT1b-infected patients, with non-severe fibrosis: STREAGER | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

A phase 3, global, multicenter, open-label study to investigate the efficacy of elbasvir/grazoprevir fixed-dose combination for 8 weeks in treatment-naïve, HCV GT1b-infected patients, with non-severe fibrosis: STREAGER

Abergel A, Hezode C, Asselah T, et al. A phase 3, global, multicenter, open-label study to investigate the efficacy of elbasvir/grazoprevir fixed-dose combination for 8 weeks in treatment-naïve, HCV GT1b-infected patients, with non-severe fibrosis: STREAGER. The International Liver Congress. Paris, France; 2018.

Publication Type:

Conference Proceedings

Authors:

Abergel, A.; Hezode, Christophe; Asselah, T; et, al

Source:

The International Liver Congress, Paris, France (2018)

Cited On:

Treatment-Naive Genotype 1b Without Cirrhosis

Export Citation:

RIS Format

Top